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Cerebral sinovenous thrombosis (CSVT) complicates therapy in 1-2% of children and 
young adults with acute lymphoblastic leukaemia (ALL) (Qureshi et al. 2010; Ranta 
et al. 2015; Caruso et al. 2006). In childhood, it has a mortality of 8-13% and can 
cause long-term neurological morbidity (deVeber et al. 2001; Ranta et al. 2015; 
Wasay et al. 2008) In addition, ALL therapy may be compromised by a reluctance to 
interrupt anticoagulation for intrathecal treatment and delayed/missed doses of L-
asparaginase due to concern about thrombus progression or recurrence (Silverman et 
al. 2001). 
 
The aim of this retrospective study was to identify individuals who developed CSVT 
during ALL therapy on the Medical Research Council (MRC) UKALL 2003 trial 
(http://www.isrctn.com/ISRCTN07355119) and to characterise their thrombotic risk 
factors, presenting features, management and outcome. 
 
Between 2003 and 2011, 45 UK centres participated in the trial, which recruited 
children and young adults aged 1- 24 years. This was a randomised study to 
investigate use of minimal residual disease (MRD) monitoring to guide the intensity 
of ALL therapy (Vora et al. 2014; Vora et al. 2013). Pegylated (PEG) asparaginase 
(Oncaspar®; MEDAC GmBH, Germany) 1000 units/m2 intra-muscularly was 
administered twice during the induction phase. All participants received oral 
dexamethasone 6mg/m2/day throughout induction, interim maintenance and 
maintenance phases.   
 
CSVT cases were identified by screening adverse event reports for central nervous 
system (CNS) thrombosis and grade III/IV serious adverse events in the 
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coagulation/thrombosis category.  Reporting forms were sent to individual centres for 
collection of additional data.  Ethical requirements were covered by overall consent 
for trial participation. Individuals with CSVT were compared to the remaining trial 
population, who did not have CSVT, using information from the study database. 
Statistical significance was measured for categorical variables using the Pearson chi-
squared test. The overall effect of all variables was assessed using binary logistic 
regression. 
 
Amongst 3126 trial participants, 46 cases of CSVT were identified. Information was 
returned for 45 cases, 2 of which were excluded as arterial events.  43 cases of CSVT 
were included in the final analysis, giving an incidence of 1.4%.   
 
Table I compares the demographic features and disease characteristics between 
individuals who developed CSVT and those who did not. The CSVT cohort was 
significantly older, and were more likely to have high-risk cytogenetics but this effect 
was not independent of age. 33/43 (77%) of CSVT occurred during induction therapy.  
Median time from leukaemia diagnosis to thrombosis was 29 days (IQR: 22-35).  All 
cases had received L-asparaginase prior to CSVT and 32/43 (74%) had received 2 
doses. 77% of cases occurred within 3 weeks of the second dose of L-asparaginase 
(Fig. 1).     
 
All cases were symptomatic.  Frequent presenting features were neurological 
impairment (65%), seizures (56%) and headaches (47%).  Concurrent intracranial 
haemorrhage (ICH) was present in 13 cases and cerebral infarction in 5. 
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Additional risk factors for thrombosis included hospital stay (22 cases), immobility 
for > 3 days (5), infection (5), dehydration (3) and use of an oestrogen-containing oral 
contraceptive pill (2). 17 cases (40%) had no additional risk factor. A thrombophilia 
screen was performed in 11 cases (26%) and was normal in 8.  Two had a reduced 
Protein S level and 1 was heterozygous for the Factor V Leiden (F506Q) mutation.  
21 individuals had an anti-thrombin (AT) level measured, of which 10 were below the 
reference range.  Of the 10 cases that occurred post induction, 8 were hospital in-
patients at the time of presentation and 5 had > 1 additional risk factors. 
 
Anticoagulant therapy was administered to 39/43 (91%).  Three did not receive 
anticoagulation due to the presence of ICH.  The majority who were treated received 
low molecular heparin (LMWH) (97%).  AT concentrate was administered to 2 and 
fresh frozen plasma to 1. Median duration of anticoagulant therapy was 3 months 
(IQR 3-6 months).  
 
ALL therapy was modified due to CSVT in 25 cases (58%). Systemic chemotherapy 
was delayed in 10 and doses missed in 4. Intrathecal chemotherapy was delayed in 6 
and doses missed in 2. Of 42 cases who were scheduled to receive further doses of L-
asparaginase, 16 (37%) received no further doses. An additional 2 missed doses but 
had L-asparaginase re-introduced later. Of those re-exposed, the majority (22/26) 
received LMWH thromboprophylaxis during re-exposure. 
 
Four individuals with CSVT died, one due to their thrombotic event (in association 
with extensive ICH). Neurological morbidity was reported in 5 cases (12%) at a 
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median of 41 months follow up, 4 of whom had ICH at presentation. There were no 
recurrent thrombotic events.  
 
Survival of the CSVT cohort at the end of the trial period (median follow up of 70 
months) was 39/43 (91%), comparable to 93% survival for the total trial population. 
Relapse rate did not differ between those with CSVT and those without, 91% vs. 
87%, respectively (p=0.473), at the end of the trial period (Vora et al. 2013).   
  
Ranta et al. recently published a cohort of 20 children who presented with CSVT 
during ALL treatment with the Nordic Society of Paediatric Haematology and 
Oncology (NOPHO) 2008 protocol, an incidence of 1.9% (20/1038). Association with 
L-asparaginase (80% of cases occurring within 2 weeks of L-asparaginase), steroid, 
co-administration of L-asparaginase and steroid, and early stages of treatment (< 5 
months) was noted (Ranta et al. 2015).  In the NOPHO 2008 protocol L-asparaginase 
was commenced post-induction meaning that CSVT presented later after diagnosis 
than in the UK cohort. Ranta et al. did not identify an association with age, although 
this was not true for all thrombotic events on the NOPHO protocol, where the 
adjusted hazard ratio for individuals aged 15-17 years was 4.0 (Tuckuviene et al. 
2016). In contrast to the UK cohort, the NOPHO cohort had a higher thrombosis-
related mortality rate with 2 deaths (10%) although the cohort was small. ALL 
treatment was altered in 12/18 with no recurrent thrombosis despite further exposure 
to L-asparaginase in a proportion of the cohort (Ranta et al. 2015). 
 
CSVT occurring during treatment of ALL in children and young people is associated 
with a small risk of mortality and neurological morbidity, along with 
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interruption/alteration of leukaemia therapy, but no identifiable impact on relapse of 
leukaemia or survival. Re-exposure to L-asparaginase with LMWH 
thromboprophylaxis is possible without risk of recurrence. Older age is a risk factor 
for CSVT. The benefit of thromboprophylaxis, either using LMWH or AT 
concentrate, during ALL therapy in childhood has not been confirmed (Mitchell et al. 
2003; Mitchell et al. 2010). There is an ongoing trial to investigate the use of 
prophylactic Apixaban in children with recently diagnosed ALL and a CVL (Bristol-
Myers Squibb, https://clinicaltrials.gov/ct2/show/NCT02369653). 
The temporal relationship of CSVT to L-asparaginase administration during ALL 
therapy would support studies to evaluate the use of thromboprophylaxis during this 
period of increased risk. 
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